Hero Curved Left No Overlay
Relievant Medsystems Introduces Intracept Simulator System Powered by Medability for Improved and Expanded Physician Training Opportunities
Advanced technology enhances Intracept Procedure training for the treatment of vertebrogenic pain CHICAGO – IPSIS Annual Meeting – September 21, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back...
Relievant Medsystems Announces Pooled Analysis Demonstrating the Intracept Procedure Significantly Reduces Low Back Pain-related Healthcare Utilization
Findings show marked reductions in need for opioids and therapeutic lumbosacral spine injections five years post-procedure MINNEAPOLIS – September 12, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low...
Relievant Medsystems Announces Pooled 4-Year Outcomes Validating Long-Term Effectiveness of the Intracept Procedure
Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low Back Pain Minneapolis – July 20, 2023 – Relievant Medsystems, a company dedicated to transforming the...
Relievant Medsystems Introduces Next-Generation Access Instruments to Advance Intracept Procedure for Chronic Vertebrogenic Low Back Pain
Miami – ASPN Annual Conference – July 14, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the release of next-generation Intracept® Access Instruments. The new instruments...
Relievant Medsystems Announces Favorable Coverage Policy from Cigna Healthcare for the Intracept Procedure
MINNEAPOLIS – June 20, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced today that Cigna Healthcare, a health benefits provider for 19 million Americans, has established national...
Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients
MINNEAPOLIS – June 15, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the publication of three-year pooled results from two prospective clinical trials that further validate...
Relievant Medsystems Announces More Than 10,000 Patients Treated with the Intracept® Procedure for Vertebrogenic Low Back Pain
MINNEAPOLIS – May 9, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that more than 10,000 patients have been treated with the Intracept® Procedure. This is the latest in a...
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
MINNEAPOLIS – April 19, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that it has completed the close of its $50 million Series G financing....
Territory Manager – Virginia
Summary: The Relievant Territory Manager is primarily responsible for selling Relievant technologies and providing clinical and technical information to healthcare professionals and their patients to achieve Relievant’s sales objectives. Territory Managers will...
Relievant Medsystems Receives 2023 Gallup Exceptional Workplace Award
MINNEAPOLIS – March 30, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that it has received the 2023 Gallup Exceptional Workplace Award (GEWA)...
Hero Curved Left Overlay
Hero Curved Center
That’s Living
Proof.
Hero Curved Right
Welcome to the proof
of Intracept
Hero Image Text
Mattis Parturient Vestibulum Risus Sit
Morbi leo risus, porta ac consectetur ac, vestibulum at eros.

Image Text

Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Curabitur blandit tempus porttitor. Fusce dapibus, tellus ac cursus commodo, tortor mauris.
Morbi leo risus, porta ac consectetur ac, vestibulum at eros.
Chart Text
Mattis Parturient Vestibulum Risus Sit
Key Findings:
Vulputate Pellentesque Lorem Adipiscing
Key Findings:
Vulputate Pellentesque Lorem Adipiscing

Video Text
Mattis Parturient Vestibulum Risus Sit
Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Curabitur blandit tempus porttitor. Fusce dapibus, tellus ac cursus commodo, tortor mauris.
3 Column Image
The Data Is Living Proof Too

Fewer Opiods
Maecenas sed diam eget risus varius blandit sit amet non magna. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Fewer Opiods
Maecenas sed diam eget risus varius blandit sit amet non magna. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Fewer Opiods
Maecenas sed diam eget risus varius blandit sit amet non magna. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Curve Right Text
Mattis Parturient Vestibulum Risus Sit
Curve Left Text
Mattis Parturient Vestibulum Risus Sit
Curve Left Text Overlay
Icon Lists
Accordion Cards
How we’re living the proof.
Now in Effect: New Category | CPT Codes
Intracept Long Term Outcomes
New Patient Story
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Indications (Global)
As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure. See important safety information below.
Patients: See the Indications & Risks Involved
The Intracept® Procedure is indicated for patients who have had chronic low back pain for at least six months, who have tried conservative care for at least six months, and whose MRI shows features consistent with Modic changes – indicating damage at the vertebral endplates has led to inflammation.
Not every patient who meets these criteria is a candidate for the Intracept Procedure, however – in fact, there are specific characteristics indicating a patient should not be considered for the procedure. These contraindications include being pregnant, having weakened cardiac or pulmonary function, having an implanted electronic medical device in the body (such as a pacemaker or defibrillator), being diagnosed with a systemic or local infection, or having an anatomy that could be damaged unintentionally while ablating the basivertebral nerve (based on your physicians’ clinical review). The Intracept Procedure is also contraindicated in patients who are skeletally immature – which generally means individuals under the age of 18 are not candidates. There are also certain risks and precautions regarding the procedure which you should be aware of before proceeding.
Talk with your doctor about what indicates, and contraindicates, certain patients for the Intracept Procedure – as well as the risks and precautions for the procedure.
Physicians: See Indications, Contraindications, and Risks
The Intracept Procedure Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).
Use of the Intracept Procedure Intraosseous Nerve Ablation System is contraindicated in:
- Patients with severe cardiac or pulmonary compromise
- Patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal)
- Patients with active systemic infection or local infection in the area to be treated
- Patients who are pregnant
- Skeletally immature patients (generally < 18 years of age)
- Patients with active implantable pulse generators (e.g., pacemakers, defibrillators)
- Situations where unintended tissue damage may result, based on the clinical assessment by the physician
- Application with electrosurgical instruments NOT tested and specified for use with the Relievant RFG
As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure. To review the contraindications, warnings, and precautions click here.
Accordion List
Physicians
Curabitur blandit tempus porttitor. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Morbi leo risus, porta ac consectetur ac, vestibulum at eros.
Intracept Long Term Outcomes
Curabitur blandit tempus porttitor. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Morbi leo risus, porta ac consectetur ac, vestibulum at eros.
New Patient Story
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Carousel Doctor
What Physicians Are Saying About Intracept
Carousel Video
Looking for proof?
Hear from the ones living it.
Video Grid
Story
Debbie’s Story
Multiple injections, multiple failed
approaches—nothing worked.
Nullam quis risus eget urna mollis ornare vel eu leo. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ullamcorper nulla non metus auctor fringilla. Cras justo odio, dapibus ac facilisis in, egestas eget quam.
Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Donec sed odio dui. Curabitur blandit tempus porttitor. Nullam quis risus eget urna mollis ornare vel eu leo. Etiam porta sem malesuada magna mollis euismod. Curabitur blandit tempus porttitor.
Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Sed posuere consectetur est at lobortis.

Next Step forms
Access Instruments CTA
The Intracept® System:
Now with Next-Generation Access Instruments
